多囊性卵巢症候群治療市場 - 依治療類型（藥物[藥物類別（口服避孕藥、抗雄性激素）配銷通路]、手術[卵巢楔形切除術、腹腔鏡卵巢鑽孔]）及全球預測，2024年至2032年

Polycystic Ovarian Syndrome Treatment Market - By Treatment Type (Medications [Drug Class (Oral Contraceptives, Antiandrogen) Distribution Channel], Surgery [Ovarian Wedge Resection, Laparoscopic Ovarian Drilling]) & Global Forecast, 2024 - 2032

出版日期: 2024年06月06日 | 出版商:

Global Market Insights Inc. | 英文 154 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在全球 PCOS 盛行率不斷上升的推動下，2024 年至 2032 年全球多囊性卵巢症候群治療市場的複合年成長率將超過 5.8%。人們對這種疾病及其併發症的認知不斷提高，促使更多女性尋求醫療干預。

已開發國家和新興國家醫療保健預算的增加正在加強多囊性卵巢症候群先進治療和診斷工具的取得。在此背景下，2023年4月，輝凌製藥與生物創新研究院（BII）宣佈建立策略夥伴關係，共同推動女性健康領域的創新。此次合作旨在支持和資助生殖醫學領域的早期新創企業，解決女性特定病症的資金不足問題。

此外，增加的投資支持醫療研發，帶來更好的診斷工具和更有效的治療選擇。改善的醫療基礎設施和更多的財政資源有助於更好地早期發現和管理多囊性卵巢綜合症，滿足對綜合治療解決方案不斷成長的需求。

整體多囊性卵巢症候群治療市場根據治療類型和地區進行分類。

由於人們越來越認知到手術介入是治療嚴重病例的有效解決方案，手術細分市場預計到 2032 年將實現良好成長。由於非侵入性治療有時效果不佳，特別是對於有明顯症狀或併發症的女性，手術選擇可以提供更直接和實際的緩解。微創手術技術的創新改善了患者的治療效果並縮短了恢復時間，使手術成為多囊性卵巢症候群治療更可行的選擇。

到 2032 年，選擇性雌激素受體調節劑 (SERM) 藥物類藥物細分市場將佔據重要的產業佔有率，因為它們能夠有效解決與疾病相關的多種症狀。 SERM，例如克羅米芬檸檬酸鹽，廣泛用於誘導多囊性卵巢症候群女性排卵，從而改善生育結果。它們選擇性調節雌激素受體的能力有助於平衡荷爾蒙水平，降低子宮內膜增生的風險，並減輕月經週期不規則和多毛症等症狀。此外，相對於手術干預，人們越來越偏好非侵入性藥物治療方案，這增強了它們的吸引力。

由於意識的提高和診斷實踐的改進，歐洲多囊性卵巢症候群治療市場規模將在預測期內顯著擴大。公共衛生措施和教育活動的增加使人們對多囊性卵巢症候群有了更深入的了解，促使更多的人尋求治療。此外，該地區的醫療保健系統專注於改善生殖健康並提供全面的護理選擇。先進醫療技術和支持性醫療政策的可用性將促進歐洲各地獲得有效的多囊性卵巢症候群治療，從而增加市場價值。

產業生態系統分析
產業影響力
- 成長動力
  - 育齡婦女 PCOS 發生率上升
  - 提高認知和診斷
  - 政府和非政府組織的支持
  - 肥胖和久坐生活方式的發生率上升
- 產業陷阱與挑戰
  - 藥物的副作用
  - 治療費用高
成長潛力分析
監管環境
- 美國
- 歐洲
- 亞太地區
管道分析
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

主要趨勢
藥物
- 按藥物類別
  - 口服避孕藥
  - 抗雄激素
  - 胰島素增敏劑
  - 抗憂鬱藥
  - 抗肥胖
  - 選擇性雌激素受體調節劑 (SERM)
  - 其他藥物類別
- 按配銷通路
  - 醫院藥房
  - 零售藥局
  - 網路藥局
手術
- 卵巢楔形切除術
- 腹腔鏡卵巢打孔術
- 其他手術

第 6 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 7 章：公司簡介

Abbott Laboratories
AbbVie Plc
Addex Therapeutics Ltd.
AstraZeneca PLC
Bayer AG
Bristol-Myer Squibb Company
Ferring BV
Johnson and Johnson
Merck KGaA
Mylan N.V
Novartis AG
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited

簡介目錄

Product Code: 9770

Global Polycystic Ovarian Syndrome Treatment Market will show over 5.8% CAGR from 2024 to 2032, driven by increasing prevalence of PCOS globally. Rising awareness about the condition and its complications is prompting more women to seek medical intervention.

The increased healthcare budgets in developed and emerging countries are strengthening access to advanced treatments and diagnostic tools for PCOS. Against this backdrop, in April 2023, Ferring Pharmaceuticals and the BioInnovation Institute (BII) announced a strategic partnership to boost innovation in women's health. This collaboration aims to support and fund early-stage start-ups in reproductive medicine, addressing the underfunding of female-specific conditions.

Further, the augmented investments support medical R&D, leading to better diagnostic tools and more effective treatment options. The improved healthcare infrastructure and greater financial resources contribute to better early detection and management of PCOS, catering to the growing demand for comprehensive treatment solutions.

The overall polycystic ovarian syndrome treatment market is classified based on treatment type and region.

The surgery segment is set for decent growth through 2032, owing to the growing recognition of surgical interventions as effective solutions for severe cases. As non-invasive treatments sometimes fall short, especially for women with significant symptoms or complications, surgical options provide more immediate and tangible relief. The innovations in minimally invasive surgical techniques have improved patient outcomes and recovery times, making surgery a more viable option for PCOS management.

The Selective Estrogen Receptor Modulators (SERMs) drug class medication segment will hold significant industry share by 2032, due to their efficacy in addressing multiple symptoms associated with the condition. SERMs, such as clomiphene citrate, are widely used to induce ovulation in women with PCOS, thus improving fertility outcomes. Their ability to modulate estrogen receptors selectively helps in balancing hormone levels, reducing the risk of endometrial hyperplasia, and alleviating symptoms like irregular menstrual cycles and hirsutism. Moreover, the growing preference for non-invasive and pharmacological treatment options over surgical interventions enhances their appeal.

Europe polycystic ovarian syndrome treatment market size will expand at a notable pace during the forecast period, due to heightened awareness and better diagnostic practices. The increased public health initiatives and educational campaigns have led to greater understanding of PCOS, driving more individuals to seek treatment. Additionally, the healthcare system in the region focuses on improving reproductive health and offers comprehensive care options. The availability of advanced medical technologies and supportive medical policies will facilitate access to effective PCOS treatments across Europe, adding to market value.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of PCOS among women of reproductive age
  - 3.2.1.2 Rising awareness and diagnosis
  - 3.2.1.3 Support from government and non-governmental organizations
  - 3.2.1.4 Rising incidence of obesity and sedentary lifestyle
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects of medication
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.4.3 Asia Pacific
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Medications
- 5.2.1 By drug class
  - 5.2.1.1 Oral contraceptives
  - 5.2.1.2 Antiandrogen
  - 5.2.1.3 Insulin-sensitizing agents
  - 5.2.1.4 Antidepressants
  - 5.2.1.5 Anti-obesity
  - 5.2.1.6 Selective Estrogen Receptor Modulators (SERMs)
  - 5.2.1.7 Other drug classes
- 5.2.2 By distribution channel
  - 5.2.2.1 Hospital pharmacies
  - 5.2.2.2 Retail pharmacies
  - 5.2.2.3 Online pharmacies
5.3 Surgery
- 5.3.1 Ovarian wedge resection
- 5.3.2 Laparoscopic ovarian drilling
- 5.3.3 Other surgeries

Chapter 6 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 North America
- 6.2.1 U.S.
- 6.2.2 Canada
6.3 Europe
- 6.3.1 Germany
- 6.3.2 UK
- 6.3.3 France
- 6.3.4 Spain
- 6.3.5 Italy
- 6.3.6 Netherlands
- 6.3.7 Rest of Europe
6.4 Asia Pacific
- 6.4.1 China
- 6.4.2 Japan
- 6.4.3 India
- 6.4.4 Australia
- 6.4.5 South Korea
- 6.4.6 Rest of Asia Pacific
6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Mexico
- 6.5.3 Rest of Latin America
6.6 Middle East and Africa
- 6.6.1 South Africa
- 6.6.2 Saudi Arabia
- 6.6.3 UAE
- 6.6.4 Rest of Middle East and Africa